KalVista Pharmaceuticals (KALV) Misses Q2 EPS by 4c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.80), $0.04 worse than the analyst estimate of ($0.76).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Citi turns more bullish on trucking stocks
• Herbalife board approves $250M share buyback over three years
• United Community Banks completes balance sheet repositioning, expands buyback